Frederik Marmé
Impact in
- Cancer Research top 0.2%
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- Oncology top 0.2%
- PARP inhibition in cancer therapy
- Peptidase Inhibition and Analysis
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
Papers in
- Oncology 131
- HER2/EGFR in Cancer Research 39
- PARP inhibition in cancer therapy 38
- Cancer Treatment and Pharmacology 27
- Cancer Immunotherapy and Biomarkers 18
-
- Breast Cancer Treatment Studies 51
- Co-authors
- Andreas Schneeweiß (59 shared papers)Jürgen Debus (5 shared papers)Uwe Haberkorn (4 shared papers)Annette Altmann (4 shared papers)Thomas Lindner (4 shared papers)Walter Mier (4 shared papers)Clemens Kratochwil (3 shared papers)Frederik Lars Giesel (3 shared papers)
- Journals
- Annals of Oncology (35 papers)European Journal of Cancer (13 papers)Breast Cancer Research and Treatment (12 papers)Breast Care (12 papers)Clinical Cancer Research (11 papers)
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
Frederik Marmé
281 papers receiving 16.7k citations
Frederik Marmé's Hit Papers
Peers
Comparison fields: 5 of 154
- Cancer Research 4.4k
- Oncology 7.6k
- Reproductive Medicine 1.5k
- Genetics 3.0k
- Molecular Biology 4.7k
Countries citing papers authored by Frederik Marmé
This map shows the geographic impact of Frederik Marmé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frederik Marmé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frederik Marmé more than expected).
Fields of papers citing papers by Frederik Marmé
This network shows the impact of papers produced by Frederik Marmé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frederik Marmé. The network helps show where Frederik Marmé may publish in the future.
Co-authors
The 25 scholars most cited alongside Frederik Marmé, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 298 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer Hit paper breakdown → | 2019 | 1510 |
| 2 | 68 Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer Hit paper breakdown → | 2019 | 1109 |
| 3 | Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay Hit paper breakdown → | 2013 | 913 |
| 4 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk Hit paper breakdown → | 2013 | 908 |
| 5 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer Hit paper breakdown → | 2015 | 486 |
| 6 | 2013 | 463 | |
| 7 | Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants Hit paper breakdown → | 2015 | 446 |
| 8 | Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention Hit paper breakdown → | 2019 | 429 |
| 9 | Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials Hit paper breakdown → | 2021 | 409 |
| 10 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Hit paper breakdown → | 2022 | 321 |
| 11 | Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2023 | 311 |
| 12 | A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45) Hit paper breakdown → | 2022 | 286 |
| 13 | 2009 | 270 | |
| 14 | 2011 | 265 | |
| 15 | Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial Hit paper breakdown → | 2021 | 254 |
| 16 | 2012 | 240 | |
| 17 | Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Hit paper breakdown → | 2022 | 239 |
| 18 | 2016 | 221 | |
| 19 | 2013 | 216 | |
| 20 | 2018 | 191 |
About Frederik Marmé
Frederik Marmé is a scholar working on Oncology, Cancer Research, Reproductive Medicine, Pulmonary and Respiratory Medicine and Genetics, having authored 298 papers that have together received 17.0k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (51 papers), HER2/EGFR in Cancer Research (39 papers), Advanced Breast Cancer Therapies (39 papers), PARP inhibition in cancer therapy (38 papers), BRCA gene mutations in cancer (35 papers), Cancer Treatment and Pharmacology (27 papers), Ovarian cancer diagnosis and treatment (25 papers) and Cancer Immunotherapy and Biomarkers (18 papers). The work is most often cited by research in Cancer Research (4.4k citations), Oncology (7.6k citations), Reproductive Medicine (1.5k citations), Genetics (3.0k citations) and Molecular Biology (4.7k citations). Frederik Marmé has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Andreas Schneeweiß, Jürgen Debus, Uwe Haberkorn, Annette Altmann, Thomas Lindner, Walter Mier, Clemens Kratochwil, Frederik Lars Giesel, Hans‐Peter Sinn and Peter Altevogt. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Breast Cancer Research and Treatment, Breast Care and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.